Manuscript version: Author’s Accepted Manuscript
The version presented in WRAP is the author’s accepted manuscript and may differ from the published version or Version of Record.

Persistent WRAP URL:
http://wrap.warwick.ac.uk/116560

How to cite:
Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

Copyright and reuse:
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher’s statement:
Please refer to the repository item page, publisher’s statement section, for further information.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk.
The importance of a valid assessment of salt intake in individuals and populations. A scientific statement of the British and Irish Hypertension Society.

Francesco P. Cappuccio \textsuperscript{a,b} and Peter S Sever \textsuperscript{c}, on behalf of the British and Irish Hypertension Society.

\textsuperscript{a} University of Warwick, WHO Collaborating Centre for Nutrition, Warwick Medical School, Coventry, United Kingdom

\textsuperscript{b} University Hospitals Coventry & Warwickshire NHS Trust, Coventry, United Kingdom

\textsuperscript{c} Imperial College London, National Heart & Lung Institute, United Kingdom.

Running title: Salt and cardiovascular disease

Word count: 1,176

Correspondence to: British and Irish Hypertension Society
c/o In Conference Ltd
Unit 1, Q Court
Quality Street
Edinburgh, EH4 5BP
Tel: +44 (0) 131 336 4203
Email: bihs@in-conference.org.uk
Introduction

High salt† intake is a major determinant of blood pressure (BP) in individuals and populations⁴. A reduction of salt intake leads to a reduction in BP and is associated with a reduction in the incidence of cardiovascular disease (CVD)⁵-⁷. However, in the past few years, some epidemiological studies suggested the presence of a J-shaped association between salt (sodium) consumption and CVD⁸-¹⁰. These results sparked both scientific and media interest and opened a debate on the wisdom of pursuing population-wide salt reduction policies to reduce CVD, as currently recommended by most national and international health organizations, including the World Health Organization (WHO)⁹. Systematic appraisal of these studies identified a variety of pitfalls, suggesting that their results were based on flawed methodologies, including the use of biased methods of assessing salt consumption¹⁰-¹¹. The present scientific statement aims to briefly highlight the consequences of such biased estimates of exposure (salt intake) when assessing both individual salt intake (for associations with CVD) and population salt consumption (to evaluate population salt reduction programmes).

Assessment of salt intake.

The 24h urinary excretion of sodium is considered the reference method to assess salt consumption, since approximately 93% of the sodium ingested, mostly as salt†, is eliminated by the kidney in the next 24h¹². If we ate the same amount of salt every day, a single 24h urine collection would indicate with a high degree of precision how much salt we eat. However, due to the high variability of salt consumption in an individual between days, many more collections on different days would be required to characterize the habitual individual’s salt consumption¹³. Therefore multiple assessments are needed, in prospective studies, to obtain a reliable estimate of the degree of association between habitual salt consumption and future risk of CVD³,¹⁴-¹⁶. To overcome the high methodological burden of collecting complete 24h urine samples in large population-based studies

†Salt is sodium chloride – 2.5g of salt contain 1g of sodium.
in some settings, then, alternative easier methods have been proposed. Amongst those alternatives the use of ‘spot’ urine collections and the application of different formulae to derive 24h urinary sodium excretion have become of popular use\textsuperscript{4-8}. The commonest is the Kawasaki\textsuperscript{17}. This formula relies on urinary creatinine concentration from a spot collection and 24h urinary creatinine excretion predicted from age, sex, height and weight. It is, however, an inappropriate method for estimating salt intake in individuals, due to its unreliability and systematic bias\textsuperscript{18}. These extrapolations consistently overestimate at lower levels of salt intake and underestimate at higher levels, introducing a systematic bias, detected in all validation studies performed to date, including the PURE Study\textsuperscript{11} (Figure 1).

Consequences of estimating ‘individual’ sodium excretion in associations studies between salt intake and CVD.

An accurate and unbiased measurement of ‘individual’ dietary sodium consumption is paramount in etiological epidemiology. In prospective studies, where multiple complete 24h urinary sodium collections have been used to measure exposure to salt consumption, consistent and graded relationships have been described between sodium excretion and health outcomes (CVD and all-cause mortality) in general populations as well as in patients groups\textsuperscript{3, 14-16}. On the contrary, when studies have used the Kawasaki formula, a J-shaped relationship has been obtained\textsuperscript{4-8}. Finally, when a head-to-head comparison was carried out between measures of salt consumption obtained from repeated 24h urine collections compared to a spot urine, in the prospective assessment of salt and mortality, there was a graded relationship when salt consumption was assessed with multiple 24h collections (with no evidence of increased risk at lower levels up to 3g of salt per day) whereas an ‘erroneous’ J-shaped curve was generated when using the Kawasaki formula from spot urines\textsuperscript{19}. (Figure 2a) Therefore ‘spot’ urine collections with the use of the Kawasaki formula are an inappropriate method for studying associations in individuals in prospective studies, and should not be used in the context of prospective assessment of salt consumption as a predictor of health outcomes.
Consequences of estimating ‘population’ average salt consumption in the evaluation of salt reduction programmes.

An accurate and unbiased measurement of ‘average’ dietary sodium consumption in population groups is paramount in public health and policy. The knowledge of a reliable estimate of population intake will help public health professionals in several ways. First, it will establish the size of the problem (how much salt does my population eat?). Second, it will provide the gap from set targets (how much do I have to reduce the average salt consumption to achieve WHO targets of 5g per day?). Third, it will help evaluate the intervention in populations by determining changes in average intake over time. Fourth, it will inform health economic evaluations of health impact and motivate continuous political commitment. So, the choice of the right method for measuring salt consumption is equally important in this setting. In a recent study in South Africa, the validity of different formulas – including Kawasaki - applied to spot urine estimates of sodium were tested against 24h urinary sodium measurements. The study showed that these formulas all fall short of an ideal scenario when assessing the presence and size of the bias. In the case of the Kawasaki formula the size of the bias was equivalent to 5.6g of salt. The important implication of these results for policy is that all these formulas introduce a bias with large inaccuracy both in the baseline estimation and, more importantly, they do not enable them to detect smaller changes in population salt consumption over time ensuing from salt reduction programmes. For instance, if spot urines with Kawasaki estimates had been applied to the evaluation of the 8-year UK national salt reduction programme, a detection of 1.4g per day reduction achieved over that period would not have been easy to detect given the presence of a bias three times as large. Therefore, the effectiveness of the population intervention would have been missed, with crucial implications for further investments and commitments towards that public health policy. The real possibility of this scenario has been reported in the recent head-to-head comparison of an evaluation of the effectiveness of a 6-to-24 months salt-substitution programme in China within the framework of a well-controlled randomized clinical trial. Over the time of intervention there was a statistically
significant reduction in average sodium consumption of 0.35g per day (p=0.039) when assessed by 24h urinary sodium excretion. However, when spot urines with Kawasaki equation were used, the change was detected as -0.09g per day (p=0.569), a quarter of the real effect (Figure 2b). Therefore ‘spot’ urine collections with the use of the Kawasaki formula are an inappropriate method for studying population changes and should not be used in the context of a public health evaluation of the effectiveness of salt reduction programmes.

Conclusions
The evidence supporting global actions for a moderate reduction in salt consumption to prevent CVD is strong and new controversial studies, based on flawed methodology, are inappropriate to address the complex associations between salt intake and CVD outcomes and the evaluation of population salt reduction programmes. They should not overturn the ongoing concerted public health action to reduce salt intake globally.

Conflicts of Interest
FPC is a technical advisor to the World Health Organization, President and Trustee of the British and Irish Hypertension Society. PSS declares no conflict of interest.

References
1. Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ. Effect of lower sodium intake on health: systematic review and meta-analyses. Br Med J 2013; 346: f1326
2. He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 2011; 378: 380–2.
3. Cook NR, Appel LJ, Whelton PK. Lower levels of sodium intake and reduced cardiovascular risk. Circulation 2014; 129: 981-9
4. O’Donnell M, Mente A, Rangarajan S et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 2014; 371: 612–23.
5. O’Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 2011; 306: 2229–38.

6. Mente A, O’Donnell MJ, Rangarajan S, Matthew J, McQueen MJ, Poirier P, et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med 2014; 371: 601-11.

7. Mente A, O’Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet 2016; 388: 465-75.

8. Mente A, O’Donnell M, Rangarajan S, McQueen M, Dagenais G, Wielgoz A, et al. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet 2018; 392: 496-506.

9. World Health Organization. Guideline: sodium intake for adults and children. Geneva: World Health Organization; 2012. p. 1–46.

10. Cobb LK, Anderson CA, Elliott P, Hu FB, Liu K, Neaton JD, et al. Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart Association. Circulation 2014; 129; 1173-86.

11. Cappuccio FP, Beer M, Strazzullo P, on behalf of the European Salt Action Network. Population dietary salt reduction and the risk of cardiovascular disease. A scientific statement from the European Salt Action Network. Nutr Metab Cardiovasc Dis 2019; 29: 107-14.

12. Lucko AM, Doktorchick C, Woodward M, Cogswell M, Neal B, Rabi D, et al. Percentage of ingested sodium excreted in 24-hour urine collections: a systematic review and meta-analysis. J Clin Hypertens 2018; 20: 1220-9.

13. Lerchl K, Rakova N, Dahlmann A, Rauh M, Goller U, Basner M, et al. Agreement between 24-hour salt ingestion and sodium excretion in a controlled environment. Hypertension 2015; 66: 850-7.
14. Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 2016; 315: 2200-10.

15. Cook NR, Appel LJ, Whelton PK. Sodium intake and all-cause mortality over 20 years in the trials of hypertension prevention. J Am Coll Cardiol 2016; 68: 1609–17.

16. Olde Engberink RHG, van den Hoek TC, van Noorden ND, van den Born BH, Peters-Sengers H, Vogt L. Use of a single baseline versus multiyear 24-hour urine collection for estimation of long-term sodium intake and associated cardiovascular and renal risk. Circulation 2017; 136: 917-26.

17. Kawasaki T, Itoh K, Uezono K, Sasaki H. A simple method for estimating 24h urinary sodium and potassium excretion from second morning voiding urine specimen in adults. Clin Exp Pharmacol Physiol 1993; 20: 7-14.

18. Campbell N. Validation and comparison of three formulae to estimate sodium and potassium excretion from a single-morning fasting urine compared to 24-h measures in 11 countries. J Hypertens 2014; 32: 2499-500.

19. He FJ, Campbell NRC, Ma Y, MacGregor GA, Cogswell ME, Cook NR. Errors in estimating usual sodium intake by the Kawasaki formula alter its relationship with mortality: implications for public health. Int J Epidemiol 2018; 47: 1784-95.

20. Cappuccio FP. Evaluating population salt reduction programmes worldwide: the risk of cutting corners! Public Health Nutrition 2018; 21(12): 2161-3.

21. Swanepoel B, Schutte AE, Cockeran M, Steyn K, Wentzel-Viljoen E. Monitoring the South African population’s salt intake: spot urine v. 24h urine. Public Health Nutrition 2018; 21(3): 480-8.

22. Huang L, Woodward M, Stepien S, Tian M, Yin X, Hao Z, et al. Spot urine samples compared with 24-h urine samples for estimating changes in urinary sodium and potassium excretion in the China Salt Substitute and Stroke Study. Int J Epidemiol 2018; 47(6): 1811-20.
Legends to figures

**Figure 1.** Validation and comparison of the Kawasaki formula to estimate 24h urinary sodium excretion from a single morning spot urine sample in the PURE Study. On the left it is the validation in 1,083 participants from 11 countries† and on the right it is the validation in 120 participants from the Shanxi Province of China‡.

† 1083 consecutive individuals attending follow-up clinics over a period of 2-6 months; 87 from India, 153 from China and Colombia, 412 from Argentina, Brazil, Malaysia, South Africa, Turkey, 431 from Canada, Sweden, UAE. ‡ 120 participants (60 rural and 60 urban) attending either 3-year or 6-year follow-up visit.

Re-drawn from Mente A et al. J Hypertens 2014; 32: 1005-15 (left) and Peng Y et al. PLoS ONE 2016; 11(2): e0149655 (right).

**Figure 2a.** Errors in estimating usual sodium intake by the Kawasaki formula alter its relationship with mortality. Head-to-head comparison with 24h urinary sodium excretion. Re-drawn from He FJ et al. Int J Epidemiol 2018; 47: 1784-95.

**Figure 2b.** Spot urine collections with Kawasaki equation is inadequate to monitor changes in population salt reduction programmes. Head-to-head comparison with 24h urinary sodium excretion. Drawn from Huang L et al. Int J Epidemiol 2018; 47: 1811-20
Figure 1
Figure 2

(a) Multiple 24h urine collections

(b) Average population salt reduction (g/day)

Spot urines and Kawasaki

-0.35 (-0.68, -0.02) P=0.039

-0.09 (-0.41, +0.22) P=0.569